Objective: To examine the prevalence of and factors associated with fear of recurrence (FCR) following treatment for breast, ovarian, endometrial, and colorectal cancer among older women.
| BACKGROUND
There are currently approximately 15 million cancer survivors in the United States, with expectations that this number will increase to over 20 million in the next 10 years. 1 One of the most commonly reported problems of cancer survivors is fear of cancer recurrence (FCR). 2 FCR is defined as the fear, worry, or concern relating to the possibility that cancer will come back or progress in the same place or in another part of the body. 3 It also includes the perception that recurrence is unmanageable, and constitutes a threat to life. 4 FCR has been recognized as an issue of significant burden among patients with cancer and has been associated with morbidity and reduced quality of life. 2 Previous research, predominantly on short-term survivors (<5 years postdiagnosis), has shown that the percentage of cancer survivors experiencing FCR ranges from 39% to 97%, with up to 15% reporting a high level of FCR. 5 In studies with long-term (≥5 years postdiagnosis) survivors, there is still a substantial percentage ranging who report high levels of FCR (17%-35%). 2, 6 There are several theories about the mechanisms of FCR; however, more research is needed, 7 because of the complexity and heterogeneity of the factors associated with recurrence fears. According to a model by Lee-Jones, 8 the patient's emotional reaction (fear) can be the result of interpretations and cognitions of cancer threat prompted by internal cues (eg, physical symptoms) and/or external cues (eg, follow-up appointments).
Previous research has indicated that FCR is associated with numerous factors including sociodemographic variables, clinical characteristics, social resources, physical and psychological factors, and coping resources. Factors consistently shown to be associated with greater FCR include younger age, 6,9,10 the presence and severity of physical symptoms, 5, 6, 10 psychological distress, 2, 5, 10 and lower reported quality of life. 5, 9 Only a few studies have examined predic- Compared to other measures of FCR, the CWS does demonstrate some promise as it is a brief measure with strong psychometric properties (α = .87) 17 that has been validated in multiple cancer types and among survivors up to 88 years old. 18, 19 In addition, the CWS's clinical cutoff scores are empirically based. In its development, the CWS assessed sensitivity, specificity, and positive and negative predictive values at each cutoff point against 2 items of the Cancer Acceptance Scale. 20 Despite the CWS's psychometric soundness among patients with breast cancer, it has not been validated against a clinical assessment of FCR and additional research is needed to establish clinical cutoffs of the CWS used in different cancer types. Participants were asked to rate their current health status using the following questionnaire item: "In general, would you say your health is excellent, very good, good, fair or poor?" Scores ranged from 1 (excellent) to 5 (poor), with a higher score indicating worse health. Better self-rated health is highly associated with better quality of life and functioning. 22 
| Symptom score

| Global quality of life
Participants were asked to rate their current quality of life using the following item: "Overall, how would you rate your quality of life?"
Scores ranged from 0 to 10, with a higher score indicating higher overall quality of life. 23 Scores were transformed to a 0 to 100 scale for data analyses. This item has high internal reliability (α = 0.86-0.89) and has been validated among cancer survivors. 24 
| RAND-36 physical functioning subscale
Participants' physical functioning was measured using the 10-item RAND-36 physical functioning subscale. 25 Responses to the single items were (1) no, not limited at all; (2) yes, limited a little; and (3) yes, limited a lot. Single items were summed together to create the subscale score and then were transformed to a 0 to 100 scale. Higher scores indicated better physical functioning. The RAND-36 has high reliability (α > .90) 25 and has been validated among cancer survivors. 26 
| Social support construct
Participants were asked about their social support that was assessed using a 5-item scale derived from the Medical Outcomes Study Social Support Questionnaire, 27 previously used in earlier WHI-based studies. 22, 28 Responses to each item was on a 5-point scale ranging from 1 = "none of the time" to 5 = "all of the time," with higher scores indicating higher levels of social support. Raw scores were transformed to a scale of 0 to 100 for analyses. The Medical Outcomes Study Social Support Questionnaire has high reliability (α > .90) 27 and has been validated among cancer survivors. 29 The responses were summed with scores ranging from 0 to 8 with higher scores indicating higher financial toxicity (described as financial problems hereafter) after one's cancer diagnosis.
| Analyses
Descriptive statistics and univariable and multivariable logistic regression models were used to assess the association of demographic, clinical, and quality of life variables with FCR, dichotomized as <14 (low Global quality of life was dichotomized based on its median value of 8, and the others were divided into roughly equal tertiles. Variables that were strongly correlated and represented similar theoretic constructs were carefully evaluated with the most predictive retained for consideration in the final model. Multivariable logistic models were fit to each of the datasets, and results were combined using SAS PROC MIANALYZE. In a backward selection process, the least significant predictor was eliminated and the models were refit until only those predictors significant at the 0.10 level remained. As cancer type was of primary interest, it was retained in all multivariable models. All analyses were performed in SAS v9.4 (SAS Institute, Cary, NC).
3 | RESULTS (Table S1 in the online supplemental materials).
| Fear of cancer recurrence
| Sample characteristics
The demographic characteristics of participants (n = 4259) by low and high FCR and univariate predictors of FCR are presented in Table S1 .
The average age of the sample was 77.6 years (range = 64-95), and the majority were white, married, and with some college education.
The average number of years since their cancer diagnosis was 9.5 years (SD = 4.9). There were no significant differences in FCR by cancer type (P = .75). The mean FCR score was 10.84 (SD = 2.87) for all cancer types combined.
Significant differences were observed between the low and high FCR groups regarding age, race, marital status, financial problems, years since diagnosis, receipt of chemotherapy, BMI, symptom score, physical functioning, self-rated health, global quality of life, and social support. Survivors who were older at diagnosis, White, widowed/single, had fewer financial problems, were greater years from diagnosis, did not receive chemotherapy, had lower BMI and symptom scores, and had better physical functioning, self-rated health, global quality of life and social support, and had lower FCR.
| Multivariate predictors of high FCR
Multiple imputation was used to create 50 imputed datasets. Using a backward selection process on the combined model estimates, a final multivariable model was created. Cancer type was retained in all models. The final model (Table S2 in 
| DISCUSSION
This study examined the prevalence of FCR and factors associated with FCR among older, long-term cancer survivors from the WHI LILAC study. Results indicated that high levels of FCR were experienced by a small proportion (15.9%) of the sample, falling slightly lower than rates reported from previous studies among older, longterm cancer survivors. 2, 6 In addition, the proportion of participants in this study who reported a high FCR was also lower compared to other studies that used the CWS. [17] [18] [19] However, it is important to note that the current study's prevalence of high FCR is, on average, 9 years past diagnosis, which demonstrates the importance of continuing to monitor and address these long-term symptoms over time. FCR in studies of middle-aged or younger women are often cited greater fears to be associated with the unexpected, "off-time" event of cancer, interference on life's goals (children, career), the lack of peers with serious illness, and fewer coping resources than their older counterparts. 33 What was remarkable in the LILAC study of women diagnosed with cancer in their 60s and 70s is that even among this cohort of older women, we still found differences by age. This study not only corresponds to previous literature regarding age as a factor for FCR 13 but also adds to the literature on FCR among an older age cohort. Given that the mean age in our study was 77.6 years, these results point to the necessity of further breaking down age categories among those age 65 and older (eg, 65-74 vs. 75-84 years).
Women who were widowed or never married were less likely to report high FCR compared to married women. Spousal support has been found to be as a major source of social support among women with cancer. 34 Higher presence of physical and mental symptoms and lower selfrated health were found to be associated with FCR in this study corresponding with previous studies on long-term cancer survivors. 6, 9 In research among cancer survivors, knowledge of these physical and psychosocial burdens as they relate to FCR must be taken into account. In the current study, symptom score of ≥14 was the greatest predictor of high FCR, representing more than a threefold risk. Helping survivors identify and address their cancer-related symptoms can greatly influence their FCR. 37 For older women, it may be difficult discerning between a cancer-related symptom and what is assumed as an age-related condition or change. Older individuals may not report their symptoms because of the assumption that the symptom is age-related not cancer-related, which may result in underreported or untreated symptoms. Clinicians and researchers need to be aware of this potential age effect and work to foster effective patient-provider communication to treat and manage bothersome symptoms.
Receipt of chemotherapy was also associated with high FCR in this study. Previous studies, 38 but not all, 6 have found receipt of chemotherapy to be associated with FCR. The result may reflect a perception of having a more serious disease. 38 Previous studies have posited that receipt of chemotherapy can increase the perceived disruptiveness of the cancer experience and feelings of vulnerability. 4, 35 Lastly, chemotherapy is often used to reduce the risk of cancer recurrence 39 ; thus, the choice of undergoing chemotherapy might be motivated by a woman's FCR.
| Clinical implications
Despite frequent studies on FCR and its determinants, some interventions 37 
| Limitations
Several study limitations must be noted. First, the study clinical measures were self-reported and may be subject to recall and survivor bias. Second, the majority of the participants were breast cancer survivors who were white, non-Hispanic, and educated.
Thus, this study lacked diversity by race ethnicity and education.
In methodology, this study used a backward selection multiple regression model, which may result in statistically significant but spurious predictors of FCR. Further, the CWS is not validated against a clinical assessment of FCR. However, the CWS is a brief measure with strong psychometric properties that has been validated in multiple cancer types. Lastly, the LILAC cohort suffers from survivorship bias in that only those women who survived long enough following their diagnosis (an average of 9 years) to take the survey are included in the sample. The sample size of certain cancer types (eg, ovarian) limits the study generalizability and longer interval between diagnosis, and the FCR assessment may bias the results as certain cancer types do have higher likelihood of recurrence and possible higher mortality rates.
A major strength of this study is the sample size and the abundant measures of demographic, clinical, psychosocial, and quality of life variables. This study adds to the existing literature, because it is the largest to examine the prevalence and predictors of high levels of FCR among older, long-term survivors of several cancer types, a growing population that is understudied.
| Conclusion
This study aimed to identify the prevalence of and factors associated with FCR among a large sample of older, long-term cancer survivors. 
